GPN Vaccines完成全额认购的1000万美元私募配售，以推进Gamma-PN™（一种潜在的首创非血清型依赖性肺炎球菌疫苗）的研发-动脉网

GPN Vaccines Closes Fully Subscribed US$10 Million Private Placement to Advance Gamma-PN™, a Potentially First-in-Class Serotype-Independent Pneumococcal Vaccine

CISION 等信源发布 2026-11-02 19:30



可切换为仅中文







Proceeds to support Phase 2-enabling activities for Gamma-PN, including cGMP manufacturing, expansion of the Company's OPA-testing capabilities and planned submission of an IND to the FDA

所得款项用于支持 Gamma-PN 的第二阶段赋能活动，包括 cGMP 生产、扩大公司 OPA 检测能力以及计划向美国食品药品监督管理局（FDA）提交新药临床试验申请（IND）。

NEW YORK and ADELAIDE, Australia

纽约和澳大利亚阿德莱德

，

Nov. 2, 2026

2026年11月2日

/PRNewswire/ --

/美通社/ --

GPN Vaccines, Inc.

GPN疫苗公司

, a clinical-stage biotechnology company developing a new generation of broadly protective bacterial vaccines designed to overcome the limitations of serotype-specific vaccination, today announced the closing of its US$10 million private placement financing with participation from new and existing investors.

，一家处于临床阶段的生物技术公司，致力于开发新一代广谱保护性细菌疫苗，旨在克服血清型特异性疫苗的局限性，今日宣布完成1,000万美元的私募融资，新老投资者均有参与。

Proceeds from the financing will support preparations to advance the Company's lead vaccine candidate, Gamma-PN™, into Phase 2 clinical development, including cGMP batch manufacturing, expansion of its opsonophagocytic activity (OPA) testing laboratory, and submission of the Investigational New Drug (IND) application to the U.S.

融资所得将用于支持推进公司领先疫苗候选产品 Gamma-PN™ 进入二期临床开发的准备工作，包括 cGMP 批次生产、扩大其调理吞噬活性（OPA）检测实验室，以及向美国提交新药临床试验申请（IND）。

Food and Drug Administration (FDA)..

美国食品药品监督管理局（FDA）

Gamma-PN is an investigational, serotype-independent pneumococcal vaccine designed to address a fundamental limitation of currently available serotype-specific vaccines. More than 100 serotypes of

Gamma-PN 是一种在研的、非血清型依赖性的肺炎球菌疫苗，旨在解决现有血清型特异性疫苗的根本局限性。超过100种血清型的

Streptococcus pneumoniae

肺炎链球菌

exist, yet currently available vaccines provide protection against only a subset, requiring manufacturers to continually develop vaccines incorporating additional serotypes. Gamma-PN is designed to generate immune responses against protein antigens shared across all pneumococcal strains, offering the potential to elicit protection independent of capsular serotype..

存在，然而目前可用的疫苗仅能针对部分血清型提供保护，这就要求制造商不断开发包含更多血清型的疫苗。Gamma-PN 旨在引发针对所有肺炎链球菌菌株共有的蛋白质抗原的免疫反应，从而有望产生不依赖于荚膜血清型的保护作用。

'For decades, pneumococcal vaccine development has focused on expanding the number of serotypes included in increasingly complex products,' said Tim Hirst, Ph.D., Chairman and CEO of GPN Vaccines. 'Gamma-PN is designed to take a fundamentally different approach by targeting protein antigens inherent to all pneumococcal strains, with the goal of providing broad protection regardless of serotype.

“几十年来，肺炎球菌疫苗的开发一直侧重于增加日益复杂的产品中所包含的血清型数量，”GPN Vaccines 董事长兼首席执行官蒂姆·赫斯特博士表示。“Gamma-PN 旨在采取一种根本不同的方法，靶向所有肺炎球菌菌株固有的蛋白抗原，以期提供不受血清型限制的广泛保护。”

This financing provides the resources to complete key Phase 2-enabling activities and advance a program that we believe could meaningfully expand the possibilities for pneumococcal disease prevention. We are grateful to our existing and new investors for their confidence in our vision.'.

本次融资为完成关键的二期临床准备活动并推进项目提供了资源，我们相信该项目能够显著拓展肺炎球菌疾病预防的可能性。我们感谢现有及新投资者对我们愿景的信任。

Gamma-PN has completed four Phase 1 clinical studies demonstrating safety, tolerability and immunogenicity across different adult populations. Additionally, data produced by GPN indicate that Gamma-PN generates functional OPA antibodies in humans capable of bacterial killing across multiple serotypes.

Gamma-PN已完成四项I期临床研究，证明其在不同成年人群中的安全性、耐受性和免疫原性。此外，GPN产生的数据表明，Gamma-PN能在人体内产生具有杀菌功能的OPA抗体，且对多种血清型均有效。

OPA has been used as an immunologic endpoint and, in specified contexts, as a surrogate measure in the regulatory evaluation of pneumococcal vaccines. GPN is now preparing for a multinational, randomized, controlled, double‑blinded, dose ranging study to evaluate the safety, tolerability and immunogenicity of a single dose of Gamma-PN in adults aged 50+..

OPA已被用作免疫学终点，并在特定情况下作为肺炎球菌疫苗监管评估中的替代指标。GPN目前正筹备开展一项多国、随机、对照、双盲的剂量范围研究，以评估单剂Gamma-PN在50岁及以上成人中的安全性、耐受性和免疫原性。

The global pneumococcal vaccine market exceeds $9 billion annually, led by Pfizer's Prevnar

全球肺炎球菌疫苗市场年规模超过90亿美元，由辉瑞公司的沛儿疫苗主导

注册商标

franchise and Merck's Vaxneuvance

特许经营权与默沙东的Vaxneuvance

and Capvaxive

以及 Capvaxive

. Despite decades of innovation, currently marketed vaccines remain limited by their serotype-specific design that requires multivalent manufacturing processes that can add substantial development and supply-chain complexity. Together, these factors create significant opportunity for a broadly protective, elegantly designed vaccine capable of addressing both current and emerging strains..

尽管历经数十年的创新，目前上市的疫苗仍受限于其血清型特异性设计，这种设计需要多价生产工艺，从而显著增加了开发和供应链的复杂性。这些因素共同为一个具有广泛保护力、设计精巧的疫苗创造了重大机遇，使其能够应对当前及新出现的菌株。

'The size of the pneumococcal vaccine market reflects both the enormous global disease burden and the value of effective vaccination, yet the industry is still constrained by vaccines that address serotypes individually,' said Bruce Forrest, M.D., Ph.D., MBA, Executive Chief Scientific Officer of GPN Vaccines.

“肺炎球菌疫苗市场的规模既反映了全球巨大的疾病负担，也体现了有效疫苗接种的价值，但该行业仍受限于仅能针对个别血清型的疫苗。”GPN Vaccines 执行首席科学官 Bruce Forrest 博士（医学博士、哲学博士、工商管理硕士）表示。

'Gamma-PN takes a fundamentally different approach. By targeting protein antigens common across pneumococcal strains, it is designed to generate functional immunity broadly across serotypes without requiring each one to be incorporated into the vaccine. As such, we believe Gamma-PN has the potential to upend the current serotype-specific model in a market where the leading vaccine franchise generates approximately $6.5 billion in annual sales.'.

Gamma-PN 采取了一种根本不同的方法。通过靶向在肺炎链球菌菌株中普遍存在的蛋白质抗原，它旨在在不需将每种血清型纳入疫苗的情况下，广泛激发针对各血清型的功能性免疫。因此，我们认为 Gamma-PN 有潜力颠覆当前以血清型特异性为主的模式；而在这一市场中，领先的疫苗产品系列年销售额约为 65 亿美元。

About Gamma-PN™

关于 Gamma-PN™

Gamma-PN™ is GPN Vaccines' lead investigational pneumococcal vaccine, designed to provide broad, serotype-independent protection against

Gamma-PN™ 是 GPN Vaccines 公司领先的在研肺炎球菌疫苗，旨在提供广泛的、非血清型依赖性的保护，以对抗

Streptococcus pneumoniae

肺炎链球菌

. Unlike conventional vaccines that target selected serotypes, Gamma-PN is designed to generate immune responses against protein antigens common across pneumococcal strains, with the potential to protect against more than 100 existing serotypes as well as those that may emerge in the future. Gamma-PN has completed four Phase 1 clinical studies demonstrating safety, tolerability and immunogenicity, including the generation of functional opsonophagocytic activity (OPA) responses demonstrating activity against multiple pneumococcal serotypes.

与针对选定血清型的传统疫苗不同，Gamma-PN 旨在引发针对肺炎球菌菌株中常见蛋白抗原的免疫反应，有望预防超过 100 种现有血清型以及未来可能出现的血清型。Gamma-PN 已完成四项 I 期临床研究，证明了其安全性、耐受性和免疫原性，包括产生功能性调理吞噬活性（OPA）反应，显示出对多种肺炎球菌血清型的活性。

OPA responses have been used as immunologic endpoints and, in specified contexts, as surrogate measures supporting regulatory approval of pneumococcal vaccines. GPN is preparing to advance Gamma-PN into Phase 2 clinical development..

OPA应答已被用作免疫学终点，并在特定情况下作为支持肺炎球菌疫苗监管批准的替代指标。GPN正准备推进Gamma-PN进入二期临床开发阶段。

About GPN Vaccines

关于GPN疫苗

GPN Vaccines, Inc. is a clinical-stage biotechnology company developing a new generation of broadly protective bacterial vaccines designed to overcome the limitations of serotype-specific vaccination. The Company's lead candidate, Gamma-PN™, is a potentially disruptive whole-cell pneumococcal vaccine designed to provide broad, serotype-independent protection against .

GPN Vaccines, Inc. 是一家处于临床阶段的生物技术公司，致力于开发新一代广谱保护性细菌疫苗，旨在克服血清型特异性疫苗的局限性。公司的主要候选产品 Gamma-PN™ 是一种具有潜在颠覆性的全细胞肺炎球菌疫苗，旨在提供广泛且非血清型依赖性的保护，以对抗。

Streptococcus pneumoniae

肺炎链球菌

, including current and emerging serotypes. Gamma-PN has completed four Phase 1 clinical studies demonstrating safety, tolerability and immunogenicity, and GPN is preparing to advance Gamma-PN into Phase 2 clinical development. Additionally, GPN is building a broader bacterial vaccine pipeline that includes its Gamma-SU program targeting .

，包括当前和新兴的血清型。Gamma-PN 已完成四项 I 期临床研究，证明了其安全性、耐受性和免疫原性，GPN 正准备推动 Gamma-PN 进入 II 期临床开发。此外，GPN 正在构建更广泛的细菌疫苗管线，其中包括针对 . 的 Gamma-SU 项目。

Streptococcus suis

猪链球菌

and programs targeting non-typeable

以及针对非分型

Haemophilus influenzae

流感嗜血杆菌

and

和

Moraxella catarrhalis

卡他莫拉菌

through BacVax. For more information, visit